← Back to headlines
BridgeBio Oncology Receives FDA Fast Track Status for Pancreatic Cancer Drug
BridgeBio Oncology's stock has risen following the announcement that its asset for pancreatic cancer has been granted Fast Track status by the FDA, indicating an expedited review process for the drug.
20 Apr, 20:42 — 20 Apr, 20:42
Sources
Showing 1 of 1 sources
